Aronstam A, Arblaster P G, Rainsford S G, Turk P, Slattery M, Alderson M R, Hall D E, Kirk P J
Br J Haematol. 1976 May;33(1):81-90. doi: 10.1111/j.1365-2141.1976.tb00973.x.
A double-blind controlled trial of prophylactic factor VIII therapy has been carried out on nine severe haemophiliacs at the Lord Mayor Treloar College. Infusions were given once weekly and calculated to give a post-infusion plasma concentration of at least 0.25 I.U./ml of factor VIII. This regime reduced the overall bleeding frequency by 15%. The bleeding frequency in the first 3 days post-infusion was reduced by 66%. A moderate overall reduction in morbidity was also achieved. It is calculated that to reduce the incidence of bleeding in severe haemophiliacs by 15% would require a 73% increased usage of therapeutic materials. More than twice this amount of material is likely to be needed to reduce the bleeding frequency of the same group by 66%.
在特雷洛尔勋爵市长学院，对9名重度血友病患者进行了预防性因子VIII治疗的双盲对照试验。每周输注一次，输注量经计算可使输注后血浆因子VIII浓度至少达到0.25国际单位/毫升。该方案使总体出血频率降低了15%。输注后前3天的出血频率降低了66%。发病率也实现了适度的总体降低。据计算，要将重度血友病患者的出血发生率降低15%，治疗材料的使用量需增加73%。若要将同一组患者的出血频率降低66%，可能需要两倍以上的材料量。
